

JAN 03 2009

Substitute for form 1449/PTO & 1449B/PTO-3 SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/538,245
		Filing Date	June 7, 2005
		First Named Inventor	David Feifel
		Examiner Name	ADITI DUTT
		Attorney Docket No.	1034123-000122

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	SHILLING, P.D., E. Richelson, and D. Feifel; "The effects of systemic NT69L, a neuropeptides agonist, on baseline and drug-disrupted prepulse inhibition" Behavioural Brain Research, 2003, 143: 7-14

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.